

(54) Title of the invention : STIMULI-RESPONSIVE HYDROXYUREA-STEARIC ACID CONJUGATED NANOSTRUCTURED LIPID CARRIERS FOR TARGETING TUMOUR MICRO ENVIRONMENT OF BREAST CANCER

(51) International classification	:A61P 35/00, A61K 47/48, A61K 9/127, A61K 47/28, A61K 31/7068	(71) <b>Name of Applicant :</b> <b>1)JSS COLLEGE OF PHARMACY – JSS ACADEMY OF HIGHER EDUCATION &amp; RESEARCH</b> Address of Applicant :JSS College, Post Box. 20, Near Rose Garden, Rocklands, Ootacamund, Tamil Nadu, India Ooty Tamil Nadu India
(31) Priority Document No	:NA	(72) <b>Name of Inventor :</b>
(32) Priority Date	:NA	<b>1)Dr. Jubie Selvaraj</b>
(33) Name of priority country	:NA	<b>2)R. Saranya</b>
(86) International Application No	:	<b>3)M. Esakkimuthukumar</b>
Filing Date	:01/01/1900	<b>4)Dr. Natarajan Jawahar</b>
(87) International Publication No	: NA	<b>5)Dr. Rajeshkumar Raman</b>
(61) Patent of Addition to Application Number	:NA	
Filing Date	:NA	
(62) Divisional to Application Number	:NA	
Filing Date	:NA	

## (57) Abstract :

The present invention relates to a stimuli-responsive nanostructured lipid carrier based pharmaceutical composition for targeted cancer therapy. The invention comprises a hydroxyurea–lipid conjugate, wherein hydroxyurea is chemically conjugated to a lipid moiety through a stimuli-labile linkage, and the conjugate is encapsulated within nanostructured lipid carriers. The conjugation enhances lipophilicity and compatibility with lipid matrices, while the nanocarrier system provides nanoscale particle size, stability, and sustained drug delivery. The composition remains stable under physiological conditions and selectively releases hydroxyurea in response to tumor-specific stimuli such as acidic pH, thereby improving tumor selectivity and reducing systemic toxicity. The invention provides a safe, effective, and scalable nanomedicine platform suitable for the treatment of breast cancer and other solid tumors.

No. of Pages : 24 No. of Claims : 8